Mark Chin

Mark Chin is currently the Director at Imara. Prior to that, they were a Principal at Longitude Capital from January 2012 to December 2016. Longitude Capital is a life sciences investment firm that focuses on venture growth investments in drug development and medical technology. From January 2011 to December 2012, Mark was a Consultant at The Boston Consulting Group (BCG) in their healthcare practice with an emphasis in early-stage biotechnology and pharmaceuticals. Before that, they were Corporate Development at Gilead Sciences from January 2010 to December 2010, working on BioOncology Pipeline Market Planning for T-DM1. From January 2009 to December 2009, they did Market Planning at Genentech on the same project. Mark then became an Investment Director at Arix Bioscience from January 2016 to December 2020. Prior to that, they were a Manager at Professional Service Solutions from January 2006 to December 2008, and a Senior Business Analyst at Patpatia & Associates from January 2004 to December 2006. Mark started their career as an Analyst at JMI Equity from January 2004 to December 2004.

Mark Chin has a MBA from The Wharton School, a BS in Management Science and Computer Science from the University of California San Diego, and an MSc in Biotechnology from the University of Pennsylvania.